2015
DOI: 10.1016/j.biocel.2015.01.015
|View full text |Cite
|
Sign up to set email alerts
|

The therapeutic effects of 4-phenylbutyric acid in maintaining proteostasis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

5
182
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 215 publications
(193 citation statements)
references
References 83 publications
(100 reference statements)
5
182
0
Order By: Relevance
“…This small chemical chaperone inhibits endoplasmic reticulum stress and is effective against many of endoplasmic reticulum stress-mediated diseases, such as various types of cancers, as well as neurodegenerative disorders such as Parkinson's disease. Furthermore, it imparts its anti-inflammatory activity by reducing inflammatory cytokines [23] . Meanwhile, phenylacetic acid is the metabolite of 4-Phenylbutyric acid and is believed to partially exert the pharmacological actions of the parent drug.…”
Section: Discussionmentioning
confidence: 99%
“…This small chemical chaperone inhibits endoplasmic reticulum stress and is effective against many of endoplasmic reticulum stress-mediated diseases, such as various types of cancers, as well as neurodegenerative disorders such as Parkinson's disease. Furthermore, it imparts its anti-inflammatory activity by reducing inflammatory cytokines [23] . Meanwhile, phenylacetic acid is the metabolite of 4-Phenylbutyric acid and is believed to partially exert the pharmacological actions of the parent drug.…”
Section: Discussionmentioning
confidence: 99%
“…The chemical chaperone 4 phenylbutyrate (4PBA) was found to relieve ER stress by stabilizing proteins in their native conformation and refolding misfolded proteins 201 . Given that 4PBA is already on the market (as Ammonaps in Europe and Buphenyl in the USA) for the treatment of urea cycle disorders 202,203 and is currently in phase I and II clinical trials for various (misfolded protein) diseases including amyotrophic lateral sclerosis, Parkinson disease, and Huntington disease, this drug might be a good candidate to attenu ate the unfolded protein response and proteotoxicity in cardiomyocytes (TABLE 2).…”
Section: Pharmacological Modulation Of Pqcmentioning
confidence: 99%
“…Then we evaluated the effect of ER stress on neutrophil differentiation in HL-60 cells. HL-60 cells were treated with 4-PBA, a chemical chaperone, which reduces ER stress [12], and assessed ER stress level by BiP and differentiation by CD11b differentiation marker. 4-PBA treatment reduced ER stress marker expression dose-dependently, and concomitantly both up-regulation of CD11b expression and nuclear morphological changes were observed with 2mM of 4-PBA (Fig.…”
Section: Er Stress Levels During Hematopoietic Differentiation Of Hl-mentioning
confidence: 99%